Latest news
Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of…
GenePOC Announces an Exclusive Distribution Agreement with Cardinal Health covering the US market
Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor
Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN
Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284
Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.